Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 1/2012

01.02.2012 | Anesthetic Techniques in Pain Management (GJ Brenner, Section editor)

Contemporary Insights into Painful Diabetic Neuropathy and Treatment with Spinal Cord Stimulation

verfasst von: Kai McGreevy, Kayode A. Williams

Erschienen in: Current Pain and Headache Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

A substantial body of literature is available on the natural history of diabetes, but much less is understood of the natural history of painful diabetic peripheral neuropathy (PDPN), a pervasive and costly complication of diabetes mellitus. Multiple mechanisms have been proposed, including polyol pathway activation, advanced glycosylation end-product formation, and vasculopathic changes. Nevertheless, specific treatment modalities addressing these basic issues are still lacking. The mainstay of treatment includes pharmacological management with antidepressants, anticonvulsants, and opioids, but these drugs are often limited by unfavorable side-effect profiles. For over 30 years, spinal cord stimulation (SCS) has been used extensively for the management of various chronic neuropathic pain states. In the past decade, interest in the use of SCS for treatment of PDPN has increased. This article reviews pathophysiological mechanisms of PDPN, proposed mechanisms of SCS, and the role of SCS for the treatment of PDPN.
Literatur
1.
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.PubMedCrossRef
2.
Zhao Y, Ye W, Boye KS, et al. Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities. Diabet Med. 2009;26:61–9.PubMedCrossRef
3.
• American Diabetes Association: Economic cost of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596–615. This article provides a very comprehensive overview of the cost of care for diabetes and diabetes-related comorbidities throughout the entire continuum of the health care system.
4.
Daousi C, Benbow SJ, Woodward A, et al. The natural history of chronic painful diabetic neuropathy in a community diabetes population. Diabet Med. 2006;23:1021–4.PubMedCrossRef
5.
Boulton AJ, Drury J, Clarke B, et al. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 1982;5:386–90.PubMedCrossRef
6.
Oyibo SO, Prasad YD, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002;19:870–3.PubMedCrossRef
7.
Podwall D, Gooch C. Diabetic neuropathy: clinical features, etiology and therapy. Curr Neurol Neurosci Rep. 2004;4:55–61.PubMedCrossRef
8.
Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol. 2002;50:325–66.PubMedCrossRef
9.
Kihara M, Mitsui Y, Shioyama M, et al. Effect of zenarestst, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat. Neurosci Lett. 2001;310:81–4.PubMedCrossRef
10.
Krendal DA: Diabetic neuropathies. In Neuromuscular Function and Disease: Basic Clinical and Electrodiagnositc Aspects. Edited by Brown WE, Bolton CE, Aminoff MD. Philadelphia: WB Suanders; 2002:1061–80.
11.
The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetic therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–8.
12.
Thomalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37–50.CrossRef
13.
Cameron NE, Eaton S, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973–88.PubMedCrossRef
14.
Hall KE, Liu J, Sima AA, et al. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol. 2001;86:760–70.PubMed
15.
Shah BS, Gonzales MI, Bramwell S, et al. β3, a novel auxiliary subunit for the voltage gated sodium channel is upregulated in sensory neurones following streptozocin induced diabetic neuropathy in rat. Neurosci Lett. 2001;309:1–4.PubMedCrossRef
16.
Novella SP, Inzucchi SE, Goldstein JM, et al. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229–31.PubMedCrossRef
17.
Summer CJ, Sheth S, Griffith JW, et al. The spectrum of neuropathy in diabetes and glucose tolerance. Neurology. 2003;60:108–11.
18.
Partanen J, Niskansen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:89–94.PubMedCrossRef
19.
Polydefkis M, Hauer P, Griffin JW, et al. Skin biopsy as a tool to assess distal small fiber innervations in diabetic neuropathy. Diabetes Technol Ther. 2001;3:23–8.PubMedCrossRef
20.
• Kilpatrick ES, Rigby AS, Atkin SL: The Diabetic Control and Complications Trial: the gift that keeps giving. Nat Rev Endocrinol 2009;5:537–45. This thorough review of the background and data to date of the Diabetic Control and Complications Trial provides valuable data from a cohort studied for over a quarter of a century, with detailed information on relationship of glycemic control and the entire spectrum of diabetic complications.
21.
Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med. 2008;33:389–94.PubMed
22.
• Ziegler D: Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care 2009;32 Suppl 2:S414-9. This is an excellent review of the pharmacological therapeutic options for the treatment of PDPN. Detailed information on the numbers needed to treat and harm allows for data-driven therapy for PDPN.
23.
Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34.PubMedCrossRef
24.
Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114–21.PubMedCrossRef
25.
Zeigler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70.CrossRef
26.
27.
El-Khoury C, Hawwa M, Baliki M, et al. Attenuation of neuropathic pain by segmental and supraspinal activation of the dorsal column system in awake rats. Neuroscience. 2002;112:541–53.PubMedCrossRef
28.
• Wu M, Linderoth B, Foreman RD: Putative mechanism behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies. Auton Neurosci 2008;138:9–23. This is an excellent article to read for a clear understanding of the effects of SCS on the CVS through the sympathetic system. Diagrams and layout allow for a clear understanding of the science.
29.
Croom JE, Foreman RD, Chandler MJ, et al. Cutaneous vasodilatation during dorsal column stimulation is mediated by dorsal roots and CGRP. Am J Physiol. 1997;272:H950–7.PubMed
30.
Goksel HM, Karadag O, Turaclar U, et al. Nitric oxide synthetase inhibition attenuates vasoactive response to spinal cord stimulation in an experimental model. Acta Neurochir (Wien). 2001;143:383–90.CrossRef
31.
Wu M, Komori N, Qin C, et al. Sensory fibers containing vanilliod receptor-1 (VR-1) mediate spinal cord stimulation-induced vasodilatation. Brain Res. 2006;1107:177–84.PubMedCrossRef
32.
Wu M, Komori N, Qin C, et al. Extracellular signal regulated kinase (ERK) and protein kinase B (AKT) pathways involved in spinal cord stimulation (SCS)-induced vasodilatation. Brain Res. 2008;207:73–83.CrossRef
33.
• Prager JP: What does the mechanism of spinal cord stimulation tell us about complex regional pain syndrome? Pain Med 2010;11:1278–83. This is an excellent review of how the mechanism of action of SCS informs the understanding of the neuropathic pain conditions, complex regional pain syndrome in particular.
34.
Stiller CO, Cui JG, O’Connor WT, et al. Release of gamma-aminobutyric acid in the dorsal horn and the suppression of tactile allodynia by spinal cord stimulation in mononeuropathic rats. Neurosurgery. 1996;39:367–74.PubMedCrossRef
35.
Schectmann G, Song Z, Ulitenius C, et al. Cholinergic mechanisms involved in pain relieving effect of spinal cord stimulation in a model of neuropathy. Pain. 2008;139:136–45.CrossRef
36.
Linderoth B, Stiller CO, Gunasekera L, et al. Gamma-aminobutyric acid is released in the dorsal horn by electrical spinal cord stimulation: an in vivo microdialysis study in the rat. Neurosurgery. 1994;34:484–8.PubMedCrossRef
37.
Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996;348:1698–701.PubMedCrossRef
38.
Daousi C, Benbow SJ, MacFarlane IA. Electrical stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med. 2005;22:393–8.PubMedCrossRef
39.
de Vos CC, Rajan V, Steenbergen W, et al. Effect and safety of spinal cord stimulation for the treatment of chronic pain caused by diabetic neuropathy. J Diabetes Complications. 2009;23:40–5.PubMedCrossRef
40.
Kapural L, Hayek S, Stanton-Hicks M, et al. Decreased insulin requirements with spinal cord stimulation in a patient with diabetes. Anesth Analg. 2004;98:745–6.PubMedCrossRef
41.
Jeon JY, Weiss CB, Steadward RD, et al. Improved glucose tolerance and insulin sensitivity after electrical stimulation-assisted cycling in people with spinal cord injury. Spinal Cord. 2002;40:110–7.PubMedCrossRef
Metadaten
Titel
Contemporary Insights into Painful Diabetic Neuropathy and Treatment with Spinal Cord Stimulation
verfasst von
Kai McGreevy
Kayode A. Williams
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Pain and Headache Reports / Ausgabe 1/2012
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-011-0230-2

Weitere Artikel der Ausgabe 1/2012

Current Pain and Headache Reports 1/2012 Zur Ausgabe

Anesthetic Techniques in Pain Management (GJ Brenner, Section Editor)

The Role of Image Guidance in Improving the Safety of Pain Treatment

Chronic Daily Headache (SJ Wang, Section Editor)

Pathophysiology of Medication-overuse Headache: Implications from Animal Studies

Chronic Daily Headache (SJ Wang, Section Editor)

Obesity and Chronic Daily Headache

Anesthetic Techniques in Pain Management (GJ Brenner, Section Editor)

Spinal Cord Stimulation: A Review

Invited Commentary

Ethical Challenges and Interventional Pain Medicine

Chronic Daily Headache (SJ Wang, Section Editor)

Chronic Daily Headache in Children and Adolescents

Neu im Fachgebiet AINS

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise